HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

phosphoramidic acid

urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds
Also Known As:
phosphoramidate; phosphoramidic acid, sodium salt; potassium phosphoramidate
Networked: 91 relevant articles (9 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Berkman, Clifford E: 9 articles (11/2021 - 12/2009)
2. McGuigan, Christopher: 8 articles (02/2020 - 05/2005)
3. Celewicz, Lech: 4 articles (01/2019 - 09/2013)
4. Kleczewska, Natalia: 4 articles (01/2019 - 09/2013)
5. Raushel, Frank M: 4 articles (01/2019 - 01/2017)
6. Ruszkowski, Piotr: 4 articles (01/2019 - 09/2013)
7. Taylor, Zane W: 4 articles (01/2019 - 01/2017)
8. VanBrocklin, Henry F: 4 articles (01/2019 - 12/2009)
9. Chang, Junbiao: 3 articles (01/2022 - 01/2016)
10. Liu, Bingjie: 3 articles (01/2022 - 01/2016)

Related Diseases

1. Prostatic Neoplasms (Prostate Cancer)
11/17/2021 - "These two steps were found to follow pseudo-first-order kinetics and had opposite dependencies on pH. P-N bond hydrolysis increased with decreasing pH, while spacer immolation was most rapid at physiological pH. Despite the contrasting release kinetics of these two steps, maximal payload release was observed at the mildly acidic pH (5.0-5.5), while minimal payload release occurred at physiological pH. We integrated this phosphoramidate-payload linker system into a PSMA-targeted fluorescent turn-on probe to study the intracellular trafficking and release of a fluorescent payload in PSMA-expressing prostate cancer cells. "
01/01/2016 - "Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer."
01/01/2016 - "Installation of aminohexanoic acid (AH) linkers in the phosphoramidate scaffold improved their PSMA binding and inhibition and was critical for achieving suitable in vivo imaging properties, positioning [(18)F]5 and [(18)F]6 as favorable candidates for future prostate cancer imaging clinical trials."
10/01/2015 - "In this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated. "
01/01/2019 - "Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer."
2. Neoplasms (Cancer)
3. Carcinoma (Carcinomatosis)
01/01/2009 - "All phosphoramidate derivatives 5a-e possess significantly greater inhibitory activities than the corresponding 3-hydroxypropyl derivatives 3a-e, whereby compound 5a showed the most potent inhibitory activities against cervical, pancreatic and colon carcinoma cell lines (IC(50)=5-7 microM)."
01/01/2018 - "2'-C-ethynyl-4'-F-uridine phosphoramidate prodrug displayed potent anti-dengue virus activity in the primary human peripheral blood mononuclear cell-based assay with no significant cytotoxicity in human hepatocellular liver carcinoma cell lines and no mitochondrial toxicity in the cell-based assay using human prostate cancer cell lines."
07/05/2021 - "The bis-phosphoramidate prodrug 13a with a mean (SD) IC50 of 2.5 ± 0.7 μM against the chloroquine-resistant P. falciparum W2 strain exhibited low cytotoxicity in the human hepatocellular liver carcinoma (HepG2) and normal human dermal fibroblasts (NHDF) cell lines at a concentration of 100 μM suggesting good selectivity for further structure-activity relationship investigations."
05/07/2010 - "The kinetics of the deprotection of these pro-drugs by porcine liver esterase and by a whole cell extract of human prostate carcinoma was studied by HPLC-ESI-MS/MS. The 3-(acetyloxymethoxy)-2,2-bis(ethoxycarbonyl)propyl and 3-(acetyloxy)-2,2-bis(ethoxycarbonyl)propyl groups were readily removed releasing the l-alanine methyl ester phosphoramidate nucleotide, the deprotection of the 3-(acetyloxymethoxy) derivative being approximately 20 times faster. "
4. Virus Diseases (Viral Diseases)
5. Hypoxia (Hypoxemia)

Related Drugs and Biologics

1. Prodrugs
2. Oligonucleotides
3. Antigens
4. Nucleosides
5. Acids
6. Antiviral Agents (Antivirals)
7. remdesivir
8. Albumins
9. dufulin
10. galidesivir

Related Therapies and Procedures

1. Therapeutics